Details for Patent: 7,253,286

Which drugs does patent 7,253,286 protect, and when does it expire?

Patent 7,253,286 protects LENVIMA and is included in one NDA.

This patent has fifty-one patent family members in twenty-three countries.

Summary for Patent: 7,253,286

Title:	Nitrogen-containing aromatic derivatives
Abstract:	Compounds represented by the following general formula: ##STR00001## [wherein A.sup.g is an optionally substituted 5- to 14-membered heterocyclic group, etc.; X.sup.g is --O--, --S--, etc.; Y.sup.g is an optionally substituted C.sub.6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and T.sup.g1 is a group represented by the following general formula: ##STR00002## (wherein E.sup.g is a single bond or --N(R.sup.g2)--, R.sup.g1 and R.sup.g2 each independently represent a hydrogen atom, an optionally substituted C.sub.1-6 alkyl group, etc. and Z.sup.g represents a C.sub.1-8 alkyl group, a C.sub.3-8 alicyclic hydrocarbon group, a C.sub.6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.
Inventor(s):	Funahashi; Yasuhiro (Nagoya, JP), Tsuruoka; Akihiko (Tsukuba, JP), Matsukura; Masayuki (Tsukuba, JP), Haneda; Toru (Ushiku, JP), Fukuda; Yoshio (Tsukuba, JP), Kamata; Junichi (Tsukuba, JP), Takahashi; Keiko (Ushiku, JP), Matsushima; Tomohiro (Ushiku, JP), Miyazaki; Kazuki (Tsukuba, JP), Nomoto; Ken-ichi (Tsukuba, JP), Watanabe; Tatsuo (Inzai, JP), Obaishi; Hiroshi (Tsukuba, JP), Yamaguchi; Atsumi (Tsukuba, JP), Suzuki; Sachi (Tsuchiura, JP), Nakamura; Katsuji (Tsukuba, JP), Mimura; Fusayo (Tsukuba, JP), Yamamoto; Yuji (Tsukuba, JP), Matsui; Junji (Toride, JP), Matsui; Kenji (Tsukuba, JP), Yoshiba; Takako (Tsukuba, JP), Suzuki; Yasuyuki (Kagamigahara, JP), Arimoto; Itaru (Tsukuba, JP)
Assignee:	Eisai Co., Ltd (Bunkyo-ku, Tokyo, JP)
Application Number:	10/420,466
Patent Claim Types: see list of patent claims	Compound; Composition;

Recent additions to Drugs Protected by US Patent 7,253,286

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE	206947	Feb 13, 2015	RX	Yes		Y	Y

Drugs Protected by US Patent 7,253,286

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No			Y	Y
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 7,253,286

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	P2000-320420	Oct 20, 2000
Japan	P2000-386195	Dec 20, 2000
Japan	P2001-046685	Feb 22, 2001

International Family Members for US Patent 7,253,286

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	355275
Austria	399766
Austria	419239
Australia	2001295986
Australia	2006203099